In this issue

Issue 112 • November 2021

In September, the World Health Organization’s director-general called for an extension of the moratorium on Covid-19 vaccine boosters to enable every country to vaccinate at least 40% of its population.

But despite this plea, wealthier nations including the UK, US and France have progressed with their booster programmes. Consequently, serious questions have been raised over the ethical implications of prioritising vaccinated populations over those less-wealthy areas that have yet to receive the first dose.

To find out more, we take a look at the reasoning behind booster programmes to understand why they may be needed and the criticisms against introducing them.

Also in this issue, we get to grips with the realities of optimising real-world data in the fight against rare diseases, find out why billionaires in the tech space are turning to pharma in the pursuit of a cure for ageing, speak to Tools4Patients CEO Dominique Demolle about removing the risk of the placebo phenomenon in clinical trials, and much more.

All this, plus the latest industry trends and innovations from GlobalData experts and analysts.

Eloise Mclennan, editor

Go to article: Home | Unpacking innovation in biologics Go to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: Verder Company InsightGo to article: VerderGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Controlant Company InsightGo to article: ControlantGo to article: DatwylerGo to article: BaxterGo to article: CommentGo to article: Novel therapies will drive Cushing’s syndrome market growthGo to article: Interim analysis backs Keytruda use in first-line cervical cancer therapy Go to article: Unmet needs and opportunities for axillary hyperhidrosisGo to article: Pfeiffer VacuumGo to article: HOF SonderanlagenbauGo to article: Avery Dennison Company Insight Go to article: Avery DennisonGo to article: In DepthGo to article: The reality of optimising real-world data Go to article: The ethics of vaccine boostersGo to article: Forever young: can science cure ageing? Go to article: Predicting the placebo responseGo to article: US regulators struggle to keep up with a global marketGo to article: BCG: the history and modern-day uses of the tuberculosis vaccineGo to article: BEA TechnologiesGo to article: MyonexGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Single Use SupportGo to article: SkyepharmaGo to article: In DataGo to article: Cloud hiring effortsGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue